Inhibikase Therapeutics Inc. Common Stock (IKT)

FairStock Score: 32/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a Buffett/Graham investor, I want predictable earnings, honest assets, and a margin of safety. Inhibikase is a 35-employee, clinical-stage drug developer focused on pulmonary arterial hypertension and IKT-001, an oral prodrug of imatinib mesylate. It has no meaningful product revenue: FY2024 and FY2025 revenue are shown as N/A, and FY2023 revenue was only $260,501. The losses are large and rising: FY2024 net loss was $27.5 million, FY2025 was $48.3 million, fiscal Q1 2026 ended 2026-03-31 lost $16.4 million, and fiscal Q2 2026 ended 2026-06-30 lost $19.6 million. FairStock shows trailing free cash flow of -$42.6 million and an FCF yield of -17.4%. At the $1.76 close on 2026-10-13, market cap is $245.6 million, P/E is -4.09, P/B is 2.00, ROE is -51.96%, and ROCE is -32.79%. The FairStock score is 32/100, Piotroski is 0/9, and the Lynch category is none because it lost money in each of the last four years. An Altman Z-Score of 13.95 suggests leverage is not the immediate distress signal on that calculation, but cash burn is. Any moat would come from patents, trial data, and regulatory execution - none of which are captured in current financials. Valuation rests on future clinical success, not on present earnings or assets. I see a speculative biotech option, not a Graham-style bargain.

In plain English: Inhibikase Therapeutics is a small drug research company with 35 employees. It is developing an oral medicine for pulmonary arterial hypertension, but it has no meaningful product sales and is losing money. At the $1.76 close on 2026-10-13, the price looks expensive compared with current sales and profits, though a drug developer's value can depend mostly on future trial results.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer